| Multiple criteria decision analysis for health care decision making—an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force P Thokala, N Devlin, K Marsh, R Baltussen, M Boysen, Z Kalo, ... Value in health 19 (1), 1-13, 2016 | 789 | 2016 |
| Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force K Marsh, M IJzerman, P Thokala, R Baltussen, M Boysen, Z Kaló, ... Value in health 19 (2), 125-137, 2016 | 517 | 2016 |
| Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low-and middle-income countries B Németh, A Molnár, S Bozóki, K Wijaya, A Inotai, JD Campbell, Z Kaló Journal of comparative effectiveness research 8 (4), 195-204, 2019 | 177 | 2019 |
| The life‐years saved by a deceased organ donor MA Schnitzler, JF Whiting, DC Brennan, KL Lentine, NM Desai, ... American Journal of Transplantation 5 (9), 2289-2296, 2005 | 162 | 2005 |
| Cost-effectiveness of organ donation: evaluating investment into donor action and other donor initiatives JF Whiting, B Kiberd, Z Kalo, P Keown, L Roels, M Kjerulf American Journal of Transplantation 4 (4), 569-573, 2004 | 136 | 2004 |
| The expanded criterial donor dilemma in cadaveric renal transplantation MA Schnitzler, JF Whiting, DC Brennan, G Lin, W Chapman, J Lowell, ... Transplantation 75 (12), 1940-1945, 2003 | 135 | 2003 |
| Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR rare disease special interest group S Nestler-Parr, D Korchagina, M Toumi, CL Pashos, C Blanchette, ... Value in Health 21 (5), 493-500, 2018 | 134 | 2018 |
| HTA implementation roadmap in Central and Eastern European countries Z Kaló, A Gheorghe, M Huic, M Csanádi, FB Kristensen Health economics 25, 179-192, 2016 | 107 | 2016 |
| The cost effectiveness of Apligraf® treatment of diabetic foot ulcers WK Redekop, J McDonnell, P Verboom, K Lovas, Z Kalo Pharmacoeconomics 21, 1171-1183, 2003 | 105 | 2003 |
| Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development J Bodrogi, Z Kaló British journal of pharmacology 159 (7), 1367-1373, 2010 | 93 | 2010 |
| Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments WK Redekop, EA Stolk, E Kok, K Lovas, Z Kalo, JJV Busschbach Diabetes & metabolism 30 (6), 549-556, 2004 | 92 | 2004 |
| Capacity building for HTA implementation in middle-income countries: the case of Hungary Z Kaló, J Bodrogi, I Boncz, C Dózsa, G Jóna, R Kövi, Z Pásztélyi, ... Value in health regional issues 2 (2), 264-266, 2013 | 81 | 2013 |
| Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications EG Hagenmeyer, B Häussler, E Hempel, G Grannas, Z Kaló, A Kilburg, ... Transplantation 77 (10), 1545-1550, 2004 | 80 | 2004 |
| Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries T Zelei, MJ Molnár, M Szegedi, Z Kaló Orphanet journal of rare diseases 11, 1-11, 2016 | 78 | 2016 |
| Cost‐effectiveness analysis of intensity‐modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer AT Zemplényi, Z Kaló, G Kovács, R Farkas, T Beöthe, D Bányai, ... European Journal of Cancer Care 27 (1), e12430, 2018 | 74 | 2018 |
| Recommendations for reporting pharmacoeconomic evaluations in Egypt GH Elsisi, Z Kaló, R Eldessouki, MD Elmahdawy, A Saad, S Ragab, ... Value in health regional issues 2 (2), 319-327, 2013 | 69 | 2013 |
| Differential pricing of new pharmaceuticals in lower income European countries Z Kaló, L Annemans, LP Garrison Expert review of pharmacoeconomics & outcomes research 13 (6), 735-741, 2013 | 68 | 2013 |
| Is there a reason for concern or is it just hype?–A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars A Inotai, CPJ Prins, M Csanádi, D Vitezic, C Codreanu, Z Kaló Expert opinion on biological therapy 17 (8), 915-926, 2017 | 67 | 2017 |
| Direct healthcare cost of schizophrenia–European overview G Kovács, T Almási, A Millier, M Toumi, M Horvath, K Kóczián, Á Götze, ... European Psychiatry 48, 79-92, 2018 | 65 | 2018 |
| Economic evaluation of kidney transplantation versus hemodialysis in patients with end-stage renal disease in Hungary Z Kaló, J Járay, J Nagy Progress in Transplantation 11 (3), 188-193, 2001 | 65 | 2001 |
Andras Inotai PharmD PhDCenter for Health Technology Assessment Semmelweis UniversityDirección de correo verificada de semmelweis-univ.hu
